… of this phase I study were to investigate the pharmacokinetics and … This study aimed at
exploring PK and tolerability of iv vinflunine in cancer patients with varying degrees of chronic liver …

… groups and a control group of 49 patients without LD enrolled in phase I trials). Results: …
Conclusions: The results showed that vinflunine and DVFL pharmacokinetic parameters do …

… Group (ECOG) performance status (PS) ≤ 2, no severe or uncontrolled medical conditions,
adequate haematologic count, no severe liver impairment according to international …

… This study was a noncomparative phase I/II trial. The primary objective of the phase I study
was to establish the recommended dose of the combination of vinflunine with cisplatin 80 mg/…

… Patients and methods In this phase I study, vinflunine was administered to 31 patients with
advanced malignancies as a 10-min iv infusion every 3 weeks according to an escalating …

… In a phase I study 21 in renal impaired patients, VFL Cl tot was shown to be reduced in patients
… The original design used in the present study, enabled maximizing the antitumor effects …

… The primary objective of the study was to establish the recommended dose (RD) of … In this
study, 19 patients received a total of 80 cycles of the combination of vinflunine and gemcitabine…

… Moreover, in the first Phase I study, two out of three patients with heavily pretreated MBC …
candidate for further investigation in patients with MBC. Vinflunine treatment every 3 weeks was …

… in advanced stage breast cancer. We conducted a phase I study combining VFL with epirubicin
(… profiles and to investigate potential pharmacokinetic (PK) drug–drug interaction (DDI). …

… For the special population Phase I studies, a rich-sampling blood collection … patient on
Cycle 1 for the liver dysfunction study and on Cycle 1 and Cycle 2 for the renal impairment study. …